Uriel Heresco‐Levy

6.2k total citations
72 papers, 4.7k citations indexed

About

Uriel Heresco‐Levy is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Biological Psychiatry. According to data from OpenAlex, Uriel Heresco‐Levy has authored 72 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Cellular and Molecular Neuroscience, 27 papers in Psychiatry and Mental health and 24 papers in Biological Psychiatry. Recurrent topics in Uriel Heresco‐Levy's work include Schizophrenia research and treatment (24 papers), Tryptophan and brain disorders (24 papers) and Neuroscience and Neuropharmacology Research (21 papers). Uriel Heresco‐Levy is often cited by papers focused on Schizophrenia research and treatment (24 papers), Tryptophan and brain disorders (24 papers) and Neuroscience and Neuropharmacology Research (21 papers). Uriel Heresco‐Levy collaborates with scholars based in Israel, United States and Singapore. Uriel Heresco‐Levy's co-authors include Daniel C. Javitt, Marina Ermilov, Daniel C. Javitt, Stephen R. Zukin, Gail Silipo, Bernard Lerer, Gali Bar, Richard P. Ebstein, I Kremer and Michael J. Lichtenstein and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Brain Research.

In The Last Decade

Uriel Heresco‐Levy

69 papers receiving 4.5k citations

Peers

Uriel Heresco‐Levy

CMN

PMH

BIOCH

Richard Bergeron Canada

Christian P. Müller Germany

Stephen R. Zukin United States

Stephen I. Deutsch United States

Maria Carlsson Sweden

L. Trevor Young Canada

Joshua T. Kantrowitz United States

Yukihiko Shirayama Japan

Michiko Nakazato Japan

Leif Lindström Sweden

Richard Bergeron Canada

Uriel Heresco‐Levy

2.2k ×1.0

CMN

676 ×0.5

436 ×0.3

PMH

2.0k ×1.7

646 ×0.6

BIOCH

Citations per year, relative to Uriel Heresco‐Levy Uriel Heresco‐Levy (= 1×) peers Richard Bergeron

Countries citing papers authored by Uriel Heresco‐Levy

Since Specialization

Citations

This map shows the geographic impact of Uriel Heresco‐Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uriel Heresco‐Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uriel Heresco‐Levy more than expected).

Fields of papers citing papers by Uriel Heresco‐Levy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uriel Heresco‐Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uriel Heresco‐Levy. The network helps show where Uriel Heresco‐Levy may publish in the future.

Co-authorship network of co-authors of Uriel Heresco‐Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Uriel Heresco‐Levy. A scholar is included among the top collaborators of Uriel Heresco‐Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uriel Heresco‐Levy. Uriel Heresco‐Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lifschytz, Tzuri, et al.. (2025). Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration. Translational Psychiatry. 15(1). 200–200. 1 indexed citations

Heresco‐Levy, Uriel, et al.. (2024). NMDAR Down-Regulation: Dual – Hit Molecular Target For COPD – Depression Comorbidity. Journal of Inflammation Research. Volume 17. 7619–7625.

Heresco‐Levy, Uriel & Bernard Lerer. (2023). Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Molecular Psychiatry. 29(1). 146–152. 9 indexed citations

Wolf, Gilly, Sandeep Singh, Karin Blakolmer, et al.. (2022). Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Molecular Psychiatry. 28(1). 44–58. 24 indexed citations

Levin, Raz, et al.. (2011). Hypnotizability and Sensorimotor Gating:A Dopaminergic Mechanism of Hypnosis. International Journal of Clinical and Experimental Hypnosis. 59(4). 399–405. 6 indexed citations

Levin, Raz, Uriel Heresco‐Levy, Rachel Bachner‐Melman, et al.. (2009). Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition. Psychoneuroendocrinology. 34(6). 901–908. 50 indexed citations

Lichtenberg, Pesach, et al.. (2008). Hypnotizability and Blink Rate: A Test of the Dopamine Hypothesis. International Journal of Clinical and Experimental Hypnosis. 56(3). 243–254. 10 indexed citations

Heresco‐Levy, Uriel, Daniel C. Javitt, Richard P. Ebstein, et al.. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry. 57(6). 577–585. 303 indexed citations

Heresco‐Levy, Uriel, et al.. (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry. 55(2). 165–171. 169 indexed citations

10.

Segman, Ronnen H., T Goltser, Uriel Heresco‐Levy, et al.. (2003). Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. The Pharmacogenomics Journal. 3(5). 277–283. 44 indexed citations

11.

Lichtenberg, Pesach, Ágnes Vass, & Uriel Heresco‐Levy. (2003). Politics and Psychopathology in an Arab-Israeli Patient. Psychiatry. 66(4). 360–363.

12.

Segman, Ronnen H., Uriel Heresco‐Levy, A Yakir, et al.. (2002). Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biological Psychiatry. 51(3). 261–263. 31 indexed citations

13.

Segman, Ronnen H., Uriel Heresco‐Levy, Boris Finkel, et al.. (2001). Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Molecular Psychiatry. 6(2). 225–229. 117 indexed citations

14.

Heresco‐Levy, Uriel, et al.. (1999). Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia. Archives of General Psychiatry. 56(1). 29–29. 379 indexed citations

15.

Heresco‐Levy, Uriel, et al.. (1999). Treatment-Resistant Schizophrenia and Staff Rejection. Schizophrenia Bulletin. 25(3). 457–465. 26 indexed citations

16.

Heresco‐Levy, Uriel, et al.. (1998). Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. The International Journal of Neuropsychopharmacology. 1(2). 131–135. 70 indexed citations

17.

Segman, Ronnen H., Richard P. Ebstein, Uriel Heresco‐Levy, et al.. (1997). Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatric Genetics. 7(2). 75–78. 27 indexed citations

18.

Kohn, Yoav, Richard P. Ebstein, Uriel Heresco‐Levy, et al.. (1997). Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. European Neuropsychopharmacology. 7(1). 39–43. 62 indexed citations

19.

Heresco‐Levy, Uriel, et al.. (1996). Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia. The British Journal of Psychiatry. 169(5). 610–617. 214 indexed citations

20.

Heresco‐Levy, Uriel, Daniel Brom, & David A. Greenberg. (1992). The patient rejection scale in an Israeli sample: Correlations with relapse and physician's assessment. Schizophrenia Research. 8(1). 81–87. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact